169 related articles for article (PubMed ID: 16461819)
1. Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors.
Campia U; Matuskey LA; Panza JA
Circulation; 2006 Feb; 113(6):867-75. PubMed ID: 16461819
[TBL] [Abstract][Full Text] [Related]
2. Effects of peroxisome proliferator-activated receptor-gamma activation with pioglitazone on plasma adipokines in nondiabetic patients with either hypercholesterolemia or hypertension.
Barac A; Campia U; Matuskey LA; Lu L; Panza JA
Am J Cardiol; 2008 Apr; 101(7):980-5. PubMed ID: 18359318
[TBL] [Abstract][Full Text] [Related]
3. TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone.
Martens FM; Rabelink TJ; op 't Roodt J; de Koning EJ; Visseren FL
Eur Heart J; 2006 Jul; 27(13):1605-9. PubMed ID: 16762982
[TBL] [Abstract][Full Text] [Related]
4. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study.
Hanefeld M; Marx N; Pfützner A; Baurecht W; Lübben G; Karagiannis E; Stier U; Forst T
J Am Coll Cardiol; 2007 Jan; 49(3):290-7. PubMed ID: 17239709
[TBL] [Abstract][Full Text] [Related]
5. Effect of pioglitazone on insulin sensitivity, vascular function and cardiovascular inflammatory markers in insulin-resistant non-diabetic Asian Indians.
Raji A; Gerhard-Herman MD; Williams JS; O'connor ME; Simonson DC
Diabet Med; 2006 May; 23(5):537-43. PubMed ID: 16681563
[TBL] [Abstract][Full Text] [Related]
6. Improved vascular function upon pioglitazone treatment in type 2 diabetes is not associated with changes in mononuclear NF-kappaB binding activity.
Rudofsky G; Reismann P; Grafe IA; Konrade I; Djuric Z; Tafel J; Buchbinder S; Zorn M; Humpert PM; Hamann A; Morcos M; Nawroth PP; Bierhaus A
Horm Metab Res; 2007 Sep; 39(9):665-71. PubMed ID: 17846974
[TBL] [Abstract][Full Text] [Related]
7. PPARγ activation does not affect endothelin activity in non-diabetic patients with hypertension or hypercholesterolemia.
Campia U; Matuskey LA; Tesauro M; Cardillo C; Panza JA
Atherosclerosis; 2014 Jun; 234(2):436-40. PubMed ID: 24769306
[TBL] [Abstract][Full Text] [Related]
8. Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus.
Wang CH; Ting MK; Verma S; Kuo LT; Yang NI; Hsieh IC; Wang SY; Hung A; Cherng WJ
Am Heart J; 2006 Dec; 152(6):1051.e1-8. PubMed ID: 17161050
[TBL] [Abstract][Full Text] [Related]
9. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial.
Caballero AE; Saouaf R; Lim SC; Hamdy O; Abou-Elenin K; O'Connor C; Logerfo FW; Horton ES; Veves A
Metabolism; 2003 Feb; 52(2):173-80. PubMed ID: 12601628
[TBL] [Abstract][Full Text] [Related]
10. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
[TBL] [Abstract][Full Text] [Related]
11. Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome.
Wang TD; Chen WJ; Cheng WC; Lin JW; Chen MF; Lee YT
Am J Cardiol; 2006 Oct; 98(8):1057-62. PubMed ID: 17027571
[TBL] [Abstract][Full Text] [Related]
12. Pioglitazone increases adiponectin levels in nondiabetic patients with coronary artery disease.
Patel SR; Mailloux LM; Coppola JT; Mindrescu C; Staniloae CS
Coron Artery Dis; 2008 Aug; 19(5):349-53. PubMed ID: 18580598
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor gamma (PPAR) agonism reduces the insulin-stimulated increase in circulating interleukin-6 in GH replaced GH-deficient adults.
Krag MB; Rasmussen LM; Hansen TK; Frystyk J; Flyvbjerg A; Møller N; Jørgensen JO
Clin Endocrinol (Oxf); 2009 Sep; 71(3):363-8. PubMed ID: 19067726
[TBL] [Abstract][Full Text] [Related]
14. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
Tonstad S; Retterstøl K; Ose L; Ohman KP; Lindberg MB; Svensson M
Metabolism; 2007 Sep; 56(9):1285-92. PubMed ID: 17697874
[TBL] [Abstract][Full Text] [Related]
15. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus.
Davidson M; Meyer PM; Haffner S; Feinstein S; D'Agostino R; Kondos GT; Perez A; Chen Z; Mazzone T
Circulation; 2008 Apr; 117(16):2123-30. PubMed ID: 18413496
[TBL] [Abstract][Full Text] [Related]
16. Effects of pioglitazone in familial combined hyperlipidaemia.
Abbink EJ; De Graaf J; De Haan JH; Heerschap A; Stalenhoef AF; Tack CJ
J Intern Med; 2006 Jan; 259(1):107-16. PubMed ID: 16336518
[TBL] [Abstract][Full Text] [Related]
17. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
Haberbosch W
Herz; 2007 Feb; 32(1):51-7. PubMed ID: 17323035
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity.
Krag MB; Nielsen S; Guo Z; Pedersen SB; Schmitz O; Christiansen JS; Jørgensen JO
Clin Endocrinol (Oxf); 2008 Sep; 69(3):452-61. PubMed ID: 18331610
[TBL] [Abstract][Full Text] [Related]
19. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance.
Werner C; Kamani CH; Gensch C; Böhm M; Laufs U
Diabetes; 2007 Oct; 56(10):2609-15. PubMed ID: 17623816
[TBL] [Abstract][Full Text] [Related]
20. Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus.
Sidhu JS; Cowan D; Kaski JC
Am J Cardiol; 2004 Jul; 94(2):151-6. PubMed ID: 15246889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
